Story
Regenxbio Stock Tumbles After Announcing $100 Million Public Offering
Summary
Shares of Regenxbio Inc. fell sharply in after-hours trading after the gene therapy company announced plans to raise $100 million through a public stock sale, raising investor concerns about its cash runway.
Shares of Regenxbio Inc. (NASDAQ: RGNX) plunged more than 17% in after-hours trading after the company revealed its intent to sell $100 million of its common stock in an underwritten public offering. The announcement, made after the market close, sent the stock price down to $9.25.
Details of the Proposed Offering
Regenxbio stated that the offering is subject to market and other conditions, with no assurance on whether or when it would be completed. The company also granted the underwriters a 30-day option to purchase up to an additional 15% of the shares sold, which could further increase the dilution for existing shareholders.
The offering is being managed by a syndicate of banks including Morgan Stanley, J.P. Morgan, Leerink Partners, and Mizuho, according to the company's statement.
Investor Concerns and Context
The timing of the capital raise caught investors by surprise and amplified concerns about the company's financial position. Regenxbio recently received a $100 million milestone payment from its partner AbbVie, triggered by the first patient being dosed in a Phase IIb/III trial for diabetic retinopathy.
AdThe decision to pursue dilutive equity financing so soon after receiving a significant non-dilutive cash infusion suggests pressure on the company's cash runway. Even with the AbbVie payment, Regenxbio's cash reserves are projected to fund operations only into the second quarter of 2027, highlighting the capital-intensive nature of the gene therapy sector.
Market Reaction
The combination of the surprise stock sale and underlying cash-burn concerns fueled a significant sell-off. Compounding the negative sentiment, Zacks Research downgraded RGNX shares from "hold" to "strong sell" on the same day.
The sharp decline pushed the stock price significantly below its 52-week high of $16.19 and toward the lower end of its annual trading range. The move occurred against a backdrop of a slightly negative session for the broader U.S. equity markets.
Read next
More on Stocks
Moody's Downgrades Mondi to Baa2 on Weakened Credit Metrics Amid Market Downturn
The ratings agency lowered Mondi's rating from Baa1, citing a prolonged downturn in the paper and packaging markets that has weakened the company's earnings, cash flow, and key financial ratios.
Pirelli Board Approves €1 Billion Expansion of Georgia Tire Plant
Pirelli will invest €1 billion to expand its Rome, Georgia, manufacturing facility, aiming to boost production of high-value tires and create approximately 1,000 new jobs.
Treasury Yields Rise as Traders Increase Bets on Another Fed Rate Hike
U.S. Treasury yields climbed on Tuesday, with the policy-sensitive 2-year note hitting a fresh two-year high, as markets priced in a greater than 50% chance of another Federal Reserve interest rate increase in October.
Amgen, Vicor Surge While Financials and Fitness Stocks Lag in Divergent Market Session
Amgen and Vicor Corp. were among Tuesday's top gainers, leading a day of mixed performance where significant rallies in some stocks contrasted with sharp declines in others, including LPL Financial and Planet Fitness.